Y4zxev_edited_edited_edited_edited.jpg
immutep gmbh.png

Immutep GmbH

We are global leaders in the understanding and development of therapeutics that relate to Lymphocyte Activation Gene-3 or "LAG-3” which is a cell surface molecule that plays a vital role in regulating the immune system. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.

Our objective is to harness and strengthen the power of the body’s own immune system through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.